My laboratory is developing and evaluating new imaging agents for whole-body imaging and intraoperative imaging. Our main focus is to selectively label malignant growths in vivo to allow for their detection, treatment, and removal. We believe that the next generation of selective imaging agents will result in better and more-sensitive detection of tumor tissues, which will ultimately benefit patient treatment.


Perez-Medina C, Abdel-Atti D, Zhang Y, Longo VA, Irwin CP, Binderup T, Ruiz-Cabello J, Fayad ZA, Lewis JS, Mulder WJ et al. (2014) A Modular Labeling Strategy for In Vivo PET and Near-Infrared Fluorescence Imaging of Nanoparticle Tumor Targeting. J Nucl Med, pii: jnumed.114.141861.

Brand C, Abdel-Atti D, Zhang Y, Carlin S, Clardy SM, Keliher EJ, Weber WA, Lewis JS, Reiner T (2014) In Vivo Imaging of GLP-1R with a Targeted Bimodal PET/Fluorescence Imaging Agent. Bioconjug Chem 25:1323–1330.

Irwin CP, Portorreal Y, Brand C, Zhang Y, Desai P, Salinas B, Weber WA, Reiner T (2014) PARPi-FL - a Fluorescent PARP1 Inhibitor for Glioblastoma Imaging. Neoplasia 16:432–440.

Emmetiere F, Irwin C, Viola-Villegas NT, Longo V, Cheal SM, Zanzonico P, Pillarsetty N, Weber WA, Lewis JS, Reiner T (2013) 18F-labeled-Bioorthogonal Liposomes for In Vivo Targeting. Bioconjugate chemistry 24:1784–1789.

Reiner T, Lacy J, Keliher EJ, Yang KS, Ullal A, Kohler RH, Vinegoni C, Weissleder R (2012) Imaging therapeutic PARP inhibition in vivo through bioorthogonally developed companion imaging agents. Neoplasia (New York, NY) 14:169–177 – Cover.